Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months
| Autor: | Rolf Carlsson, Thomas L. Venables, Göran Hasselgren, Karna Dev Bardhan, Kevin P J O'Kane, David Armstrong, Mustafa H. Giaffer, Samuel Chen, Nicholas J. Talley, J. R. B. Green |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.drug_class Placebo-controlled study Administration Oral Proton-pump inhibitor Severity of Illness Index digestive system Gastroenterology Drug Administration Schedule law.invention Esomeprazole Double-Blind Method Randomized controlled trial Reference Values law Internal medicine Gastroscopy otorhinolaryngologic diseases Humans Medicine Esomeprazole Sodium Omeprazole Aged Probability Aged 80 and over Dose-Response Relationship Drug Hepatology business.industry digestive oral and skin physiology Reflux Middle Aged Long-Term Care digestive system diseases Surgery Clinical trial Treatment Outcome Patient Satisfaction Gastroesophageal Reflux Female Esophagoscopy business Follow-Up Studies medicine.drug |
| Zdroj: | European Journal of Gastroenterology & Hepatology. 14:857-863 |
| ISSN: | 0954-691X |
| DOI: | 10.1097/00042737-200208000-00008 |
| Popis: | On-demand therapy may offer an effective approach to the long-term management of gastro-oesophageal reflux disease (GORD) without oesophagitis.To examine the efficacy of the novel proton pump inhibitor esomeprazole as on-demand therapy in endoscopy-negative GORD.Endoscopy-negative GORD patients who achieved complete resolution of heartburn after short-term esomeprazole or omeprazole treatment (n = 721) were randomized to esomeprazole 20 mg (n = 282), 40 mg (n = 293) or placebo (n = 146) on demand (maximum one dose/day) for 6 months. The primary and secondary efficacy endpoints were time to study discontinuation due to (i) unwillingness to continue and (ii) inadequate control of heartburn, respectively.Both doses of esomeprazole were more effective than placebo. During the 6-month period, 42% of placebo recipients discontinued treatment due to unwillingness to continue, compared with 8% and 11% of esomeprazole 20 mg and 40 mg recipients, respectively. Overall, more patients treated with esomeprazole were free from gastrointestinal symptoms after 6 months of on-demand therapy.Esomeprazole 20 mg was superior to placebo for on-demand treatment of GORD; a higher dose did not confer additional clinical benefit. Over 90% of patients were willing to continue on-demand treatment with esomeprazole 20 mg over a 6-month period. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|